Downloads: 0 | Views: 183
Informative Article | Pharmacotherapeutics | India | Volume 11 Issue 6, June 2022 | Popularity: 4.1 / 10
Will Dostarlimab Become the New Rectal Cancer Drug of Choice?
Motupalli Sankeerth Kumar, Ponnaluri Lalitha, Seelam Victor John Wilson
Abstract: Information on a recent clinical trial in the United States on a drug that has been shown to be nearly 100% effective against rectal cancer in the sample population.
Keywords: Dostarlimab, Rectal cancer, new drug of choice
Edition: Volume 11 Issue 6, June 2022
Pages: 1369 - 1369
DOI: https://www.doi.org/10.21275/SR22617214828
Make Sure to Disable the Pop-Up Blocker of Web Browser
Motupalli Sankeerth Kumar, Ponnaluri Lalitha, Seelam Victor John Wilson, "Will Dostarlimab Become the New Rectal Cancer Drug of Choice?", International Journal of Science and Research (IJSR), Volume 11 Issue 6, June 2022, pp. 1369-1369, URL: https://www.ijsr.net/getabstract.php?paperid=SR22617214828, DOI: https://www.doi.org/10.21275/SR22617214828